NASDAQ · KNSA
Kiniksa Pharmaceuticals International, plc
$97.56+$2.38 (+2.5%)
Kiniksa Pharmaceuticals International, plc’s quoted price sits in the upper half of its reported 52-week range, 0.81% below the high.
Loading market information…
NASDAQ · FOLD · USD
Stock price, earnings
Quote as of Apr 27, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Amicus Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.07% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Amicus Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. Its primary commercial offering is Galafold, an orally administered precision medicine designed for adult patients with a confirmed diagnosis of Fabry disease, specifically those exhibiting an amenable galactosidase alpha gene variant as identified by in vitro assay data. The company's pipeline also includes several investigational therapies: AT-GAA, an innovative treatment strategy for Pompe disease; various enzyme replacement therapies aimed at Pompe diseases; and AT-GTX-502, an AAV serotype gene therapy for CLN3. The latter is currently undergoing Phase 1/2 clinical studies to evaluate the safety and efficacy of a single intrathecal administration in patients with CLN3. Additionally, Amicus is exploring therapeutic approaches related to CDKL5, a gene on the X-chromosome that encodes a protein essential for regulating proper brain development. Amicus maintains strategic collaborations and licensing arrangements with prominent entities such as Nationwide Children's Hospital, the University of Pennsylvania, and GlaxoSmithKline. The company was founded in 2002 and is based in Philadelphia, Pennsylvania.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:55 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $141.52M+4.88% vs estimate |
| Q2 2024 | Aug 8, 2024 | -$0.05+8.93% vs estimate | $126.67M+4.5% vs estimate |
|---|
| Q1 2024 | May 9, 2024 | -$0.16-166.67% vs estimate | $110.40M-0.7% vs estimate |
|---|
THE ANALYST VIEW
24 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$97.56+$2.38 (+2.5%)
Kiniksa Pharmaceuticals International, plc’s quoted price sits in the upper half of its reported 52-week range, 0.81% below the high.
$221.38$0.00 (0.0%)
Cidara Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.02% below the high.
$44.18+$0.93 (+2.15%)
Scholar Rock Holding Corporation’s quoted price sits in the lower half of its reported 52-week range, 28.47% below the high.
$28.17-$0.20 (-0.7%)
Adaptive Biotechnologies Corporation’s quoted price sits in the upper half of its reported 52-week range, 8.36% below the high.
$22.30-$0.23 (-1.02%)
Legend Biotech Corporation’s quoted price sits in the lower half of its reported 52-week range, 40.53% below the high.
$31.97+$0.52 (+1.65%)
Arcutis Biotherapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.99% below the high.
$31.49$0.00 (0.0%)
Catalyst Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.29% below the high.
$74.20+$2.15 (+2.98%)
Tarsus Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 18.93% below the high.
